Inflarx NV (NASDAQ:IFRX) – Research analysts at B. Riley issued their FY2017 earnings estimates for shares of Inflarx in a research report issued on Wednesday. B. Riley analyst M. Kumar anticipates that the company will post earnings of ($0.74) per share for the year. B. Riley currently has a “Buy” rating and a $40.00 target price on the stock. B. Riley also issued estimates for Inflarx’s FY2018 earnings at ($0.82) EPS, FY2019 earnings at ($0.95) EPS, FY2020 earnings at ($1.35) EPS, FY2021 earnings at ($1.77) EPS and FY2022 earnings at ($2.04) EPS.
Other equities analysts have also recently issued research reports about the stock. BMO Capital Markets started coverage on shares of Inflarx in a report on Monday, December 4th. They issued an “outperform” rating and a $31.00 target price on the stock. Leerink Swann started coverage on shares of Inflarx in a report on Monday, December 4th. They issued an “outperform” rating and a $31.00 target price on the stock. Finally, JPMorgan Chase & Co. started coverage on shares of Inflarx in a report on Monday, December 4th. They issued an “overweight” rating and a $30.00 target price on the stock.
A hedge fund recently bought a new stake in Inflarx stock. BlackRock Inc. bought a new position in Inflarx NV (NASDAQ:IFRX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,485,896 shares of the company’s stock, valued at approximately $31,129,000. BlackRock Inc. owned about 6.35% of Inflarx as of its most recent SEC filing. 0.86% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/12/inflarx-nv-to-post-fy2017-earnings-of-0-74-per-share-b-riley-forecasts-ifrx.html.
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases.
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.